Comparing two blood thinners for atrial fibrillation in peritoneal dialysis patients
Part of Heart & circulation clinical trials.
This study tests if apixaban (a newer blood thinner) is safer and works as well as warfarin (a standard blood thinner) for patients on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). It aims to reduce the risk of stroke and bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been on peritoneal dialysis for at least 3 months
- You have atrial fibrillation (not related to heart valve disease) and need a blood thinner
- Your stroke risk score (CHA2DS2-VASc) is 2 or higher
- If you could become pregnant, you agree to use effective birth control during the study
- You do not have conditions that make blood thinners unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two strategies for managing atrial fibrillation (irregular heartbeat) in people on dialysis: one uses a blood thinner called apixaban to prevent strokes, and the other does not. The goal is to find out which approach is safer and more effective for this specific group.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
This study compares two blood thinners, apixaban and rivaroxaban, to see which is safer and works better for veterans with atrial fibrillation (irregular heartbeat). If you're already taking one of these, the study will assign you to one of them.
This study tests whether a common blood thinner (apixaban) alone is as safe and effective as combining it with another drug (clopidogrel) to prevent future strokes in people who have both atrial fibrillation and narrowing in the arteries leading to the brain. It aims to find the best way to reduce stroke risk while minimizing bleeding.
This study compares two blood thinners, edoxaban and apixaban, to see how they affect new brain lesions seen on MRI in people who have had a stroke and also have atrial fibrillation. It aims to find which might be safer for preventing future brain damage.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.